[PT-01]*Wastewater surveillance for public health decision-making: opportunities and challenges across multiple pathogens*
○Jillian Sarah Gauld1(1. Gates Foundation (United States of America))
検索条件
フリーワード：
開催年：
2021〜2025
すべてのイベントから検索します。検索結果は最大１万件まで表示されます。
〜
検索条件
| フリーワード： | |
|---|---|
| 開催年： | 2021〜2025 |
すべてのイベントから検索します。検索結果は最大１万件まで表示されます。
〜
検索結果(605)
[PT-02]The changing landscape of vaccine access in the developing world
○Kim Mulholland1,2(1. Murdoch Children’s Research Institute, Melbourne (Australia), 2. London School of Hygiene and Tropical Medicine (UK))
[PT-03]From Molecule to Ethics: Navigating Future Vaccines’ On- and Off-Targets
○Ken J Ishii1,2,3(1. Division of Vaccine Science, The Institute of Medical Science, The University of Tokyo (IMSUT) (Japan), 2. International Vaccine Design Center, IMSUT (Japan), 3. UTOPIA, The University of Tokyo (Japan))
[S01-01]A wastewater-integrated genomic surveillance framework enhances global outbreak tracking and response
○Joshua Levy1(1. Scripps Research (United States of America))
[S01-02]Leveraging targeted amplicon sequencing for wastewater environmental surveillance
○Alex Shaw1, Shannon Fitz1, Joyce Akello1, Catherine Troman1, Jon Rigby1, Jaspreet Mahindroo1, Anton Spadar2, Tabassum Iqbal1, Dilip Abraham3, Michael Owusu4, Nicholas Grassly1(1. Imperial College London (UK), 2. London School of Hygiene & Tropical Medicine (UK), 3. Christian Medical College Vellore (India), 4. Kwame Nkrumah University of Science and Technology (Ghana))
[S01-03]Towards WHO 2030 Goals: Wastewater Surveillance as a Complementary Tool for Measles Elimination in the South African Context
○Mukhlid Yousif1,3, Nkosenhle Ndlovu1, Victor Mabasa1, Chenoa Sankar1, Nosihle Msomi1, Emmanuel Phalane1, Natasha Singh1, Sipho Gwala1, Fiona Els1,2, Mokgaetji Macheke1, Sibonginkosi Maposa1, Kerrigan McCarthy1,3(1. National Institute for Communicable Diseases (NICD) (South Africa), 2. Gauteng City-Region Observatory (GCRO) (South Africa), 3. Department of Virology, School of Pathology, Faculty of Health Sciences, University of Witwatersrand (South Africa))
[S01-04]Evolution of Sewage Surveillance in Dhaka, Bangladesh: From Polio Monitoring to Multi-Pathogen and Early Warning for Public Health Impact
○Benjamin Fuller1, Isobel Blake2, Julia Ledien2, Md Ohedul Islam1, Firdausi Qadri3, AGS Faruque3, Rashidul Haque3, Mami Taniuchi 1(1. University of Virginia (United States of America), 2. Imperial (UK), 3. Icddr,b (Bangladesh))
[S01-05]Integrating diagnostic and environmental data to model and map enteric infectious disease transmission: The Planetary Child Health & Enterics Observatory (Plan-EO) and SPRINGS initiatives
Nasif Hossain2, Margaret Kosek1, Venkataraman Lakshmi3, Benjamin Zaitchik4, Lauren Gardner4, ○Josh M Colston1(1. The University of Virginia School of Medicine (United States of America), 2. The University of Virginia Environmental Institute (United States of America), 3. The University of Virginia School of Engineering & Applied Science (United States of America), 4. Johns Hopkins University (United States of America))
[S02-01]Durability and diversity of human upper airway immune memory
○Sydney Ramirez1,2, Farhoud Faraji1,2, Paul Lopez1, Thamotharampillai Dileepan3, Marc Jenkins3, Shane Crotty1,2(1. La Jolla Institute for Immunology (United States of America), 2. University of California, San Diego (United States of America), 3. University of Minnesota Medical School (United States of America))
[S02-02]Controlling durability of vaccine-induced antibody responses
○Yoshimasa Takahashi1(1. Japan Institute for Health Security, National Institute of Infectious Diseases (Japan))
[S02-03]Age-Related and Individual Heterogeneity in Vaccine Responses
○Yoko Hamazaki Hamazaki1,2(1. Center for iPS Cell Research and Application, Graduate School of Medicine, Kyoto University (Japan), 2. Laboratory of Immunobiology, Graduate School of Medicine, Kyoto University (Japan))
[S02-04]Cellular Senescence Contributes to Persistent Inflammation Following SARS-CoV-2 Infection
○Shunya Tsuji1, Eiji Hara2(1. Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University (Japan), 2. Department of Molecular Biology, Research Institute for Microbial Diseases, The University of Osaka (Japan))
[S02-05]Coordinating Mitochondrial Reprogramming in Aged naïve T Cells Restores Anti-Tumor Immunity
○Kenji Chamoto1(1. Department of Cancer Immunology and Photodynamic Therapy, Graduate School of Medicine, Kyoto University (Japan))
[S02-06 (P02-32)]In vitro induction of human germinal centre B-cells
○David Geoffrey Priest1, Wataru Ise2, James B. Wing1,3(1. Human Single Cell Immunology Team, Division of Microbiology and Immunology, Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Osaka, Japan (Japan), 2. Regulation of Host Defense Team, Division of Microbiology and Immunology, Center for Infectious Disease Education and Research, Osaka University, Osaka, Japan (Japan), 3. Human Single Cell Immunology Laboratory, Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan. (Japan))
[S03-01]Ebolavirus inclusion bodies - a target for novel antiviral strategies?
○Thomas Hoenen1(1. Friedrich-Loeffler-Institut (Germany))
[S03-02]Spatiotemporal regulation of membrane remodelling by the ESCRT pathway
○Juan Martin Serrano1(1. Department of Infectious Diseases, Faculty of Life Sciences & Medicine, King's College London (UK))
[S03-03]Virus-Host Interactions: Connecting Mechanisms with Implications for Arenavirus Pathogenesis
○Allison Groseth1(1. Friedrich-Loeffler-Institut (Germany))
[S03-04]VIral Pathogenesis and Vaccine Development
○Takeshi Ichinohe1(1. Institute of Medical Science, The University of Tokyo (Japan))
[S03-05]Calcium-Dependent Host Signaling Pathways Orchestrating the Multistep Processes of Influenza A Virus Entry and Propagation
○Yusuke Ohba1, Yoichiro Fujioka1(1. Department of Cell Physiology, Faculty of Medicine, Hokkaido University (Japan))
[S03-06 (P02-13)]Evolutionary dynamics of heparan sulfate utilization by SARS-CoV-2
○Shuhei Higuchi1, Hisashi Arase1,2,3,4(1. Arase Lab, Center for Advanced Modalities and DDS (CAMaD), Osaka University (Japan), 2. Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University (Japan), 3. Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University (Japan), 4. Center for Infectious Disease Education and Research, Osaka University (Japan))
[S03-07 (P02-06)]Genome-Scale CRISPR Screen Identifies a Host Factor Involved in the Persistence and the Inclusion Body Formation of Borna Disease Virus
○WenChing Luo1,2, Hiromichi Matsugo1,2, Akiko Makino1,2, Keizo Tomonaga1,2,3(1. Graduate School of Biostudies, Kyoto University (Japan), 2. Institute for Life and Medical Sciences, Kyoto University (Japan), 3. Graduate School of Medicine, Kyoto University (Japan))
[S04-01]Alternative Dosing Schedules for Pneumococcal Conjugate Vaccines
○LAYMYINT YOSHIDA1(1. Institute of Tropical Medicine, Nagasaki University (Japan))
[S04-02]Epidemiological studies evaluating the effectiveness of vaccines in preventing adult respiratory infections.
○Konosuke Morimoto1(1. Insitute of Tropical Medicine, Nagasaki University (Japan))
[S04-03]Vaccination Policy in Japan: Post-Pandemic Developments and Future Directions
○Motoi Suzuki1(1. Japan Institute for Health Security (Japan))
[S04-04]How National Laboratory Networks Inform Vaccine Updates and Public Health Decisions: Thailand’s Experience
○Pilailuk Akkapaiboon Okada1(1. National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Thailand (Thailand))
[S04-05 (P02-17)]A mouse model for human typhoid fever
○Hoan T Pham1, Masatomo Morita2, Kohei Yamazaki3, Azusa Hiyoshi 1, Andreas J. Bäumler4, Toshio Kodama 1, Hirotaka Hiyoshi 1(1. Institute of Tropical Medicine, Nagasaki University (Japan), 2. Department of Bacteriology I, National Institute of Infectious Diseases, NIID (Japan), 3. Laboratory of Veterinary Public Health, School of Veterinary Medicine, Kitasato University (Japan), 4. Department of Medical Microbiology and Immunology, School of Medicine, University of California at Davis (United States of America))
[S04-06 (P01-21)]Novel evidence of MDH and MQO pair functioning as a dual NAD(P)H:ubiquinone oxidoreductase system in Campylobacter jejuni.
○Augustin Tshibaka Kabongo1,2,6, Rajib Acharjee1,2, Takaya Sakura1,2, Ozan Gundogdu3, Jun-ichi Kishikawa4, Tomoo Shiba4, Kiyoshi Kita1, Daniel Ken Inaoka1,2,5(1. School of Tropical Medicine and Global Health, Nagasaki University (Japan), 2. Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 3. London School of Hygiene & Tropical Medicine (LSHTM), London (UK), 4. Department of Applied Biology, Graduate School of Science and Technology, Kyoto Institute of Technology (Japan), 5. Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo (Japan), 6. Faculty of Medicine, Public Health and and Pharmacy, University of Mbujimayi (Democratic Republic of the Congo))
[S05-01]Public-Private Partnerships in Advancing Vaccines
○Hayato Urabe1(1. Global Health Innovative Technology Fund (Japan))
[S05-02]Outlook for vaccination and global elimination of leishmaniasis
○Greg Matlashewski1(1. McGill Univ, Canada (Canada))
[S05-03]Development of LST antigen and its use as a surrogate marker for immunogenicity
Sreenivas Gannavaram1, Kamaleshwar P Singh2, Swarnendu Kaviraj2, Shinjiro Hamano3, Greg Matlashewski4, Hira L Nakhasi1, Sanjay Singh2, ○Abhay R Satoskar4,5(1. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA. (United States of America), 2. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India, (India), 3. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. The Joint Usage/Research Center on Tropical Disease, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. (Japan), 4. Department of Microbiology and Immunology, McGill University, Montreal, Canada. (Canada), 5. Department of Pathology and Microbiology, Ohio State University, Columbus, OH, USA. (United States of America))
[S05-04]Advancement in Leishmania vaccination development and its role in global elimination of leishmaniasis
○Hira Nakhasi1(1. Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA (United States of America))
[S05-05]Value of a Controlled Human Infection Model to Test the Efficacy of Leishmania Vaccines
Eva A. Iniguez1, Tiago D. Serafim1, Jesus G. Valenzuela1, Josh R. Lacsina1, ○Shaden Kamhawi1(1. National Institutes of Health (United States of America))
[S05-06]Progress in creating effective strategies for the control and elimination of leishmaniasis.
Kamaleshwar P Singh1, Swarnendu Kaviraj1, Sreenivas Gannavaram2, Abhay R Satoskar3, Shaden Kamhawi4, Shinjiro Hamano5, Greg Matlashewski6, Hira L Nakhasi 7, ○Sanjay Singh8(1. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India (India), 2. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA (United States of America), 3. Department of Pathology and Microbiology, Ohio State University, Columbus, OH , USA (United States of America), 4. Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, 20852, USA (United States of America), 5. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan. (Japan), 6. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada (Canada), 7. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA (United States of America), 8. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India, (India))
[S05-07]Leishmania vaccine: Upcoming clinical trials, key challenges to overcome, and global partnerships
○Kawsar Talaat1(1. Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health (United States of America))
[S06-01]Regulation of the germinal center B cell response to vaccination
○Ali Ellebedy1(1. Washington University School of Medicine (United States of America))
[S06-02]Development of Vaccines and Immunotherapy Using Alphaviruses
○Wataru Akahata1,2(1. VLP Therapeutics, Inc. (United States of America), 2. VLP Therapeutics Japan, Inc. (Japan))
[S06-03]The translational research for cancer vaccines
○Xiawei Wei1(1. West China Hospital, Sichuan University (China))
[S06-04 (P02-41)]High-avidity antigen-specific CD4+T cells exhibit distinct, public and convergent TCR sequence features
○Dongyun Lu1,4, Celine Chua1,4, Xinxin Xue1,4, Naila Shinwari1,4, Isao Ito2, Takao Hashiguchi3, Hideki Ueno1,4(1. Department of Immunology, Graduate School of Medicine, Kyoto University (Japan), 2. Department of Respiratory Medicine, Kyoto University Hospital (Japan), 3. Institute for Frontier Life and Medical Sciences, Kyoto University (Japan), 4. Kyoto Immunomonitoring Center (KIC) (Japan))
[S06-05]Next-generation mRNA vaccines for infectious diseases and cancer
○Satoshi Uchida1,2(1. Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo (Japan), 2. Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion (Japan))
[EL-01]Vaccine Development Using Different Regulatory Pathways
○Kawsar Talaat1(1. Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health (United States of America))
[ST-01 (P02-39)]Preclinical study of PfRipr5 formulated with human-compatible adjuvants for blood-stage malaria vaccine development
○Eizo Takashima1, Hikaru Nagaoka1, Hidenori Kimura2, Akihisa Fukushima2, Takafumi Tsuboi3(1. Division of Malaria Research, Proteo-Science Center, Ehime University (Japan), 2. Vaccines, Sumitomo Pharma (Japan), 3. Division of Cell-free Science, Proteo-Science Center, Ehime University (Japan))
[ST-02]Infection and the Kidney - An overview
○Anjali Satoskar1(1. The Ohio State University Medical Center (United States of America))
[ST-03 (P02-29)]Enhancement of host cell apoptosis and inflammatory responses via NF-κB signaling by Toxoplasma gondii Programmed Cell Death 5
○Shu Nakamura1, Akari Nishida1, Yoshifumi Nishikawa1(1. Obihiro University of Agriculture and Veterinary Medicine (Japan))
[P001]Regulation of hepatitis B virus replication by modulating endoplasmic reticulum stress
○Md. Golzar Hossain1, Keiji Ueda2(1. Department of Microbiology and Hygiene, Bangladesh Agricultural University (Bangladesh), 2. Division of Virology, Department of Microbiology and Immunology, Graduate School of Medicine, Osaka University, Japan (Japan))
[P003]Reactivation of latent HIV-1 by the selective glucocorticoid receptor modulator AZD9567
○sharmeen fayyaz1, rishikesh lotke3, isabell Haussmann2, Moritz Peterson2, Daniel Sauter2(1. National Institute of Virology (Pakistan), 2. 1.Institute for Medical Virology and Epidemiology of Viral Diseases (Germany), 3. 3.Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig (Germany))
[P005]Identification of host factors involved in Ebola virus particle formation
○Hina Miyazaki1, Shungo Adachi2, Kosuke Takada1, Shintaro Shichinohe1, Itsuki Anzai1, Tokiko Watanabe1,3,4(1. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. National Cancer Center Research Institute (Japan), 3. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan), 4. Center for Advanced Modalities and DDS (CAMaD), The University of Osaka (Japan))
[P007]Smart Pools, Safer Nations: mEGA, An Enhanced Metagenomic System for Scalable Viral Surveillance.
○Maryam Sani Lawal1,2,3, Kyoko Hayashida1,2, Tatsuki Sugi 1,2, Patrick Reteng 4, Junya Yamagishi1,2,5(1. Graduate School of Infectious Diseases, Hokkaido University, Sapporo, Japan. (Japan), 2. Division of Collaboration and Education International Institute for Zoonosis Control (Japan), 3. National Reference Laboratory, Nigeria Centre for Disease Control and Prevention, Abuja, Nigeria (Nigeria), 4. Department of Infection and Immunity, Luxembourg Institute of Health Luxembourg City, Luxembourg (Japan), 5. Global Station for Zoonosis Control, GI-CoRE, Hokkaido University, Sapporo, Hokkaido, Japan (Japan))
[P009]Development of anti-influenza therapeutics using host-directed antisense oligonucleotides
○Makoto Shimooka1, Tomomi Kirino1, Harumi Yamaguma2, Natsumi Kameoka2, Hina Miyazaki1, Itsuki Anzai1, Shintaro Shichinohe1, Satoshi Obika3,4,5,6, Yuuya Kasahara2,5, Tokiko Watanabe1,3,4(1. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. National Institutes of Biomedical Innovation, Health and Nutrition (Japan), 3. Center for Infectious Disease Education and Research, The University of Osaka (Japan), 4. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 5. Graduate School of Pharmaceutical Sciences, The University of Osaka (Japan), 6. Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka (Japan))
[P011]An mRNA-LNP vaccine induces cross-protective immunity against emerging H5N1 influenza viruses in mice
○Qingxin Li1, Shintaro Shichinohe1, Hiroki Tanaka2,3, Jessica Anindita3, Sara Yoshimoto1, Kaewaroon Nantaporn1,4, Makoto Shimooka1, Itsuki Anzai1, Hidetaka Akita2,3, Tokiko Watanabe1,2,5(1. Department of Molecular Virology, Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and DDS, The University of Osaka (Japan), 3. Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Tohoku University (Japan), 4. The National Vaccine Institute (Thailand), 5. Center for Infectious Disease Education and Research (CiDER), The University of Osaka (Japan))
[P013]Molecular detection and genomic characterization of Chikungunya virus in Dengue-suspected patients during the 2019 Dengue outbreak in Yangon, Myanmar
○Merveille Kapandji1, Htin Lin2, Maurine Mumo Mutua1, Qiang xu1,3, Ryosaku Oshiro1, Catarina Harumi Oda1, Khine Mya Nwe1, Shyam Prakash Dumre4, Kyaw Zin Thant5, War War Aung2, Aye Aye Khin2, Hlaing Myat Thu2, Takeshi Urano6, Kouichi Morita1,3,6,7, Yuki Takamatsu1, Mya Myat Ngwe Tun1,3,6,7(1. Institute of Tropical Medicine, Nagasaki University (Japan), 2. Department of Medical Research, Ministry of Health (Myanmar), 3. DEJIMA Infectious Disease Research Alliance, Nagasaki University (Japan), 4. Central Department of Microbiology, Tribhuvan University (Nepal), 5. Myanmar Academy of Medical Science (Myanmar), 6. Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University (Japan), 7. Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine, Nagasaki University (Japan))
605 件中 ( 1 - 50 )
- 1
- ...